BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 31 October 1996.
The NIH investigators reported that in a randomized, controlled study of 60 HIV infected patients, in 31 subjects mean CD4+ T-cell counts doubled from 428 cells at baseline to 916 cells per cubic millimeter at 12 months. These patients received IL-2 plus standard antiviral therapy, and had CD4 counts greater than 200 cells per cubic millimeter at the time they began treatment.
Among 29 people receiving standard antiviral therapy alone, the mean CD4+ T-cell count decreased from 406 to 349 in the same period. Importantly, no significant differences in HIV RNA plasma (viral load) or p24 antigen levels were seen between the groups over the year of treatment. Furthermore, there was no increase in viral load in IL-2-treated patients over the course of the study.
The study was reported by Joseph A. Kovacs, M.D., H. Clifford Lane, M.D., and their colleagues, including Gwen Fyfe, M.D., of Chiron, which supplied the IL-2 used in the study. Chiron markets recombinant IL-2 under the trade name of Proleukin (aldesleukin) for injection for treatment of metastatic renal cell cancer. The full text of the NIH press release describing the study's results is attached following this release.
"These data underscore the potentially important and complementary role that IL-2 could play in the expanding array of weapons to fight HIV infection and its consequences," noted Magnus Lundberg, president of Chiron Therapeutics, which markets Proleukin.
"Given the tremendous recent progress in reducing viral load through use of new protease inhibitors, the next step needed is to strengthen the immune system to fight the opportunistic infections that impact life. We look forward to continuing the evaluation of Proleukin therapy in people infected with HIV."
Chiron has provided IL-2 for 12 NIH studies investigating IL-2 in people infected with HIV, and has sponsored nine other studies on its own.
"Chiron has recently completed two randomized trials of outpatient continuous infusion IL-2 which have also shown substantial CD4 increases among the IL-2 treated patients compared to patients treated with antivirals alone," said Gwen Fyfe, M.D., director of clinical research.
"These trials have focused on improving the tolerability of IL-2 therapy and its ease of use in this indication. We are now studying subcutaneous administration of IL-2 and have encouraging data regarding its immunologic activity. The current trial is part of our ongoing collaboration with the NIAID and highlights our commitment to optimizing the potential benefit and clinical utility of IL-2 in HIV disease."
Study results, including those published today, have continued to show that IL-2 therapy leads to substantial increases in CD4+ T-cells in some people with HIV; these data suggest that IL-2 treatment may complement the actions of antiretrovirals, including protease inhibitors.
Protease inhibitors were not used in this study. The clinical data from the NIH study suggests that the CD4+ T-cells induced by IL-2 therapy are functional, and thus may provide benefits by reducing opportunistic infections. In addition, the side effects of IL-2 infusion as reported in today's NEJM were more manageable than those seen in previous reported studies using a higher dose of IL-2 administered intravenously.
"Our goal is to determine a tolerable dosing regimen that will deliver clinical benefits for patients," said Lundberg. "Recent studies have shown that IL-2's effects on the immune system can be sustained with regimens that are generally well-tolerated. Thus we are adding to the knowledge base with each succeeding study."
Chiron's bDNA HIV RNA probe tests were used to measure virus in study subjects. Results from a series of clinical studies presented or published by Dr. John Mellors of the University Of Pittsburgh during 1995 and 1996 have established that viral load is an excellent predictor of disease progression and complements measurement of CD4 counts in the management of HIV infection.
Chiron has a number of programs across its businesses directed at HIV infection as well as the opportunistic infections that frequently plague people with HIV. Chiron Vision markets the Vitrasert Implant, the first drug delivery system for localized, sustained therapy for cytomegalovirus (CMV) retinitis in people with AIDS.
Chiron has candidate vaccines for CMV and HIV in Phase 2 clinical trials, and a vaccine for genital herpes in Phase 3 trials. A gene therapy approach for treating HIV infection is in clinical trials. Together with Johnson & Johnson, Chiron introduced the first home HIV test service, Confide.
For additional information, the public can contact the Professional Services Group at Chiron by dialing 1-800/CHIRON-8 (1-800/244-7668).
Chiron Corp., headquartered in Emeryville, near San Francisco, is a science-driven healthcare company that combines diagnostic, vaccine, and therapeutic strategies for controlling disease.
Chiron participates in four global markets: diagnostics, including immunodiagnostics, critical care diagnostics, and new quantitative probe tests; ophthalmic surgical products for the correction of vision; pediatric and adult vaccines; and therapeutics, with an emphasis on oncology and infectious diseases.
Chiron also has research programs underway in gene therapy and gene transfer, combinatorial transfer, combinatorial chemistry, cardiovascular disease and critical care.
CONTACT: Chiron Corp. Larry Kurtz, 510/601-2476 Kimberly Kraemer Sankaran, 510/601-2412
NIH release follows
IL-2 Therapy Doubles CD4+ T-Cell Counts in HIV-Infected People
In a one-year study of HIV-infected people, infusions of the immune system protein interleukin-2 (IL-2) have resulted in dramatic and sustained increases in the primary immune system cells depleted during HIV infection, according to investigators at the National Institutes of Health (NIH).
In the study, patients randomly assigned to receive IL-2 plus standard antiretroviral therapy had mean CD4+ T-cell counts that increased from 428 cells per cubic millimeter of blood (mm3) at baseline to 916 cells/mm3 at month 12.
Among patients randomly assigned to receive standard antiretroviral therapy alone, mean CD4+ T-cell counts decreased from 406 cells/mm3 to 349 cells/mm3. CD4+ T-cell are the main targets of HIV; the progressive loss of these cells leads to the symptoms of the acquired immunodeficiency syndrome (AIDS).
Joseph A. Kovacs, M.D.; H. Clifford Lane, M.D.; and their colleagues report their findings in the Oct. 31 issue of "The New England Journal of Medicine." Dr. Kovacs is a senior investigator in the Critical Care Medicine Department at the NIH Clinical Center, and Dr. Lane is the clinical director of the National Institute of Allergy and Infectious Diseases (NIAID).
"This work highlights the potential role of immune-based therapies in the treatment of HIV-infected people," said Anthony S. Fauci, M.D., NIAID director.
Significantly, the amount of HIV in the blood of study patients receiving IL-2 therapy remained stable over time. Previous studies had shown that IL-2 treatment can result in transient bursts of virus production in some patients, but the current data clearly indicate that these bursts do not lead to sustained increases in viral load.
In addition, the side effects of IL-2 infusions in the current study were much less severe than those seen in previous studies using higher doses of intravenous IL-2.
"Our study has clearly demonstrated that IL-2 therapy can have a substantial positive impact on the major immunologic abnormality associated with HIV infection, the loss of CD4+ T-cell, without leading to an overall increase in the level of HIV in the bloodstream or to unmanageable toxicities," said Dr. Kovacs.
Despite flu-like symptoms and other side effects during IL-2 infusions, patients in the study reported feeling as well overall as patients not receiving IL-2, according to a quality of life analysis presented at the XIth International Conference on AIDS in Vancouver, B.C.
"We are encouraged that the increases in CD4+ T-cells observed in this study did not come at the expense of a patient's overall quality of life," said Dr. Kovacs. "Additional work by our group has show that other dosing regimens, especially subcutaneous administration of lower IL-2 doses, can further reduce toxicity."
All immunologic studies performed thus far suggest that the CD4+ cells that proliferate during IL-2 therapy are functional, Dr. Lane noted. As further evidence of this, "the current study has provided the first clinical data that IL-2 therapy may beable to prevent new AIDS-related conditions or death," he said.
"Among individuals randomized to standard antiretroviral therapy, five people developed AIDS-related symptoms or died, as compared to two in the group randomized to IL-2 in addition to standard antiretroviral therapy. In each instance, these events occurred in patients with low CD4+ T-cell levels. Phase III studies are needed to accurately determine the clinical benefits of IL-2 therapy."
IL-2, originally called T-cell growth factor, is produced in the body by T-cells and has potent effects on the maturation and proliferation of a number of cell types, including T-cell, B-cells and natural killer cells. Commercially, IL-2 is produced by recombinant DNA technology and is licensed in the United States for the treatment of patients with metastatic renal cell cancer. The recombinant IL-2 used in the NIAID study was produced by Chiron Corp. of Emeryville.
Study Details
In the study, 60 patients with baseline CD4+ T-cell counts above 200/mm3 of blood were randomly assigned to receive IL-2 plus licensed antiretroviral therapy, or antiretroviral therapy alone. IL-2 was administered at a starting dose of 18 million International Units (IU) a day for five days every two months. The dose was reduced as needed; the mean dose used in the latter part of the study was approximately 8 million IU/day.
The most common side effects during IL-2 administration were fatigue or malaise, reported by patients during 44 percent of the five-day treatment cycles, and headache, reported during 7 percent of treatment cycles. The most common laboratory abnormality, seen during 8 percent of the treatment cycles, was an elevation in bilirubin levels, indicating an effect on the liver.
The elevations were not accompanied by clinical symptoms, and levels returned to normal after the treatment period. The investigators note that toxicities decreased in frequency during later rounds of treatment as IL-2 dosages were reduced.
In an extension phase of the trial, the investigators found that increases in CD4+ T-cells could be sustained for more than two years by continuing to administer IL-2 on an individualized schedule. In five patients, CD4+ T-cell counts remained over 1000/mm3 for at least 18 months after discontinuing IL-2.
"To date, no combination of antiretroviral agents has been shown capable of inducing increases in CD4+ T-cell counts of this magnitude or duration," the authors write.
Because Il-2 targets the immune system rather than HIV itself, viral mutations should not reduce its effectiveness, the investigators note. In contrast, resistance to antiretroviral drugs occurs because of HIV's high rate of mutation.
"The lack of resistance to IL-2 helps explain why some patients have continued to respond to IL-2 therapy even 50 months after beginning therapy," said Dr. Kovacs.
While the current study of IL-2 enrolled only patients with CD4+ T-cell counts above 200/mm3, additional Phase II work in NIAID's AIDS Clinical Trials Group is being planned in patients with more advanced disease. Ronald T. Mitsuyasu, M.D., director of the UCLA Center for AIDS Research and Education and associate professor at the UCLA School of Medicine, is focusing his efforts on patients with lower CD4+ T-cell counts, and will assess IL-2 given with antiretroviral regimens that include a protease inhibitor.
Next Step: A Phase III Trial of IL-2
The NIH investigators currently are working with scientific colleagues in the United States and abroad to develop a Phase III strategy to determine whether the increases in CD4+ T-cells achieved with IL-2 therapy will translate to fewer AIDS-related complications and improved survival for HIV-infected people.
Professor David Cooper M.D., director of the National Centre in HIV Epidemiology and Clinical Research in Sydney, Australia, has studied IL-2 and is working closely with the NIH investigators in the development of a Phase III plan for evaluating IL-2 in HIV-infected patients with CD4+ T-cell counts greater than 400 cells/mm3. He comments, "Complementing antiretroviral therapy with IL-2 is an attractive approach to the treatment of HIV-infected people, offering the opportunity to reduce the amount of virus in the body while boosting the immune system's capacity. We look forward to a trial that will clarify the long-term clinical benefits associated with the IL-2 induced increases in CD4+ T-cells."
Professor Maxime Seligmann, M.D., chairman of the Scientific Council of the ANRS in France, comments, "When given in conjunction with antiretrovirals, IL-2 has the potential to directly boost the immune system in a way that may be of clinical benefit.
The only way to definitively establish this is in the context of a well-designed Phase III trial."
In collaboration with Yves Levy, M.D., Professor Seligmann currently is conducting a trial comparing intravenous and subcutaneous modes of IL-2 administration. This study will allow a detailed analysis of the immunologic changes seen in people receiving IL-2 therapy and provide insights into how best to administer IL-2.
Dr. Kovacs' and Dr. Lane's co-authors on the NIH study include Susan Vogel, B.S., Jeffrey M. Albert, Ph.D., Judith Falloon, M.D., Richard T. Davey, M.D., Robert Walker, M.D., Michael A. Polis, M.D., M.P.H., Katherine Spooner, M.D., Julia A. Metcalf, B.A., all of NIAID: Henry Masur, M.D., of the Clinical Center's Critical Care Medicine Dept.; Michael Baseler, Ph.D., and Robin J. Dewar, Ph.D., of SAIC Inc., Frederick, Md; and Gwendolyn Fyfe, M.D., of Chiron Corp., Emeryville.
NIAID and the Clinical Center are components of the National Institutes of Health. NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, asthma and allergies. NIH is an agency of the Public Health Service, U.S. Department of Health and Human Services. References: Kovacs JA, et al. Sustained increases in CD4 counts in HIV-infected patients treated with interleukin-2 during a randomized, controlled trial. N Engl J Med 1996;335:1350-56.
Barrick B, et al. Quality of life and symptom distress in HIV-infected persons receiving intravenous interleukin-2 (IL-2). XIth International Conference on AIDS (abstract #2306), Vancouver, B.C., July 7-12 1996.
HIV-infected individuals and their physicians interested in NIH clinical trials involving interleukin-2 can call 1-800-AIDS-NIH. Information on other HIV clinical trials is available by calling 1-800-TRIALS-A.
NIAID press releases, fact sheets and other materials are available on the Internet via the NIAID home page at http://www.niaid.nih.gov.
CONTACT: National Institutes of Health Greg Folkers, 301/402-1663 folkers@nih.gov
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961031
BW961031
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .